BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
前收盘价
US$390.94
−US$8.76 · -2.19%
盘中时间采用ET。市场数据可能有所延迟。
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
日内区间
当前US$390.94
52周区间
当前US$390.94
盘中时间采用ET。市场数据可能有所延迟。
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
日内区间
当前US$390.94
52周区间
当前US$390.94
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 53.43亿 USD | 38.1亿 USD | 24.59亿 USD | 14.16亿 USD | 11.76亿 USD |
| 销货成本 | 6.69亿 USD | 5.94亿 USD | 3.8亿 USD | 2.86亿 USD | 1.65亿 USD |
| 毛利 | 46.74亿 USD | 32.16亿 USD | 20.79亿 USD | 11.29亿 USD | 10.11亿 USD |
| 研究与开发 | 21.46亿 USD | 19.53亿 USD | 17.79亿 USD | 16.41亿 USD | 14.59亿 USD |
| 销售、一般及管理费用 | 20.81亿 USD | 18.31亿 USD | 15.08亿 USD | 12.79亿 USD | 9.9亿 USD |
| 营业费用 | 42.27亿 USD | 37.84亿 USD | 32.87亿 USD | 29.19亿 USD | 24.5亿 USD |
| 利息收入 | 7050.5万 USD | 4783.6万 USD | 7400.9万 USD | 5248万 USD | 1575.7万 USD |
| 利息支出 | 5823.4万 USD | — | — | — | — |
| 折旧和摊销 | 1.42亿 USD | 1.72亿 USD | 8767.5万 USD | 6627.8万 USD | 4645.7万 USD |
| 营业利润 | 4.47亿 USD | −5.68亿 USD | −12.08亿 USD | −17.9亿 USD | −14.39亿 USD |
| 净利润 | 2.87亿 USD | −6.45亿 USD | −8.82亿 USD | −20.04亿 USD | −14.58亿 USD |
公司数据更新于 2026年11月22日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$426.5
上涨空间 9.10%报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB2.55亿2.43%105.27亿 USD0.44%US$199.54-2.05%
First Trust NYSE Arca Biotechnology Index FundFBT1.09亿3.80%28.67亿 USD0.55%US$257-2.20%
Capital Group Global Growth Equity ETFCGGO9693万0.85%113.97亿 USD0.47%US$34.38-4.34%
Global X China Biotech ETF (HKD)2820.HK6543.13万12.33%6.22亿 HKD0.68%HK$63.56-4.22%
Capital Group Global Equity ETFCGGE2615.84万0.82%32.03亿 USD0.47%US$31.25-3.67%
Capital Group New Geography Equity ETFCGNG1923.4万0.67%28.62亿 USD0.64%US$29.91-4.13%
Capital Group International Equity ETFCGIE1648万0.70%23.48亿 USD0.54%US$33.33-3.22%
VanEck Biotech ETFBBH1540.12万3.03%5.03亿 USD0.35%US$239.49-1.31%
iShares Biotechnology ETFIBB
First Trust NYSE Arca Biotechnology Index FundFBT
Capital Group Global Growth Equity ETFCGGO
Global X China Biotech ETF (HKD)2820.HK
Capital Group Global Equity ETFCGGE
Capital Group New Geography Equity ETFCGNG
Capital Group International Equity ETFCGIE
VanEck Biotech ETFBBHAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。